Cargando…

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA

PARP1 and PARP2 detect DNA breaks, which activates their catalytic production of poly(ADP-ribose) that recruits repair factors and contributes to PARP1/2 release from DNA. PARP inhibitors (PARPi) are used in cancer treatment and target PARP1/2 catalytic activity, interfering with repair and increasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langelier, Marie-France, Lin, Xiaohui, Zha, Shan, Pascal, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2023
Materias:	Biomedicine and Life Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038340/ https://www.ncbi.nlm.nih.gov/pubmed/36961901 http://dx.doi.org/10.1126/sciadv.adf7175

Ejemplares similares

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022)

Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020)

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
por: Langelier, Marie-France, et al.
Publicado: (2014)

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023)

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
por: Zhang, Xudong, et al.
Publicado: (2023)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains
por: Langelier, Marie-France, et al.
Publicado: (2018)

RNA binding induces an allosteric switch in Cyp33 to repress MLL1-mediated transcription
por: Blatter, Markus, et al.
Publicado: (2023)

Client binding shifts the populations of dynamic Hsp90 conformations through an allosteric network
por: Lopez, Abraham, et al.
Publicado: (2021)

Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition
por: Ogden, Tom E H, et al.
Publicado: (2021)

Molecular basis of hUHRF1 allosteric activation for synergistic histone modification binding by PI5P
por: Mandal, Papita, et al.
Publicado: (2022)

Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
por: Eustermann, Sebastian, et al.
Publicado: (2015)

The antiactivator FleN uses an allosteric mechanism to regulate σ(54)-dependent expression of flagellar genes in Pseudomonas aeruginosa
por: Chanchal,, et al.
Publicado: (2021)

Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex
por: Hurdiss, Daniel L., et al.
Publicado: (2022)

Mechanisms of Nucleosome Reorganization by PARP1
por: Maluchenko, Natalya V., et al.
Publicado: (2021)

Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage
por: Steffen, Jamin D., et al.
Publicado: (2016)

Unfolding of core nucleosomes by PARP-1 revealed by spFRET microscopy
por: Sultanov, Daniel, et al.
Publicado: (2017)

Lnc956-TRIM28-HSP90B1 complex on replication forks promotes CMG helicase retention to ensure stem cell genomic stability and embryogenesis
por: Zhang, Weidao, et al.
Publicado: (2023)

HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP-ribose modifications
por: Langelier, Marie-France, et al.
Publicado: (2021)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Novel suction-based in vivo cutaneous DNA transfection platform
por: Lallow, Emran O., et al.
Publicado: (2021)

Genotype-specific precision tumor therapy using mitochondrial DNA mutation-induced drug release system
por: Li, Yanan, et al.
Publicado: (2023)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas
por: Tiek, Deanna M., et al.
Publicado: (2022)

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022)

RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes
por: Kondegowda, Nagesha Guthalu, et al.
Publicado: (2023)

Inactivation of the tumor suppressor gene Apc synergizes with H. pylori to induce DNA damage in murine gastric stem and progenitor cells
por: He, Jiazhuo, et al.
Publicado: (2023)

Inhibitors of PARP: Number crunching and structure gazing
por: Rudolph, Johannes, et al.
Publicado: (2022)

Lactate induces vascular permeability via disruption of VE-cadherin in endothelial cells during sepsis
por: Yang, Kun, et al.
Publicado: (2022)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair
por: Liu, Liu, et al.
Publicado: (2022)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020)

FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair
por: Pinedo-Carpio, Edgar, et al.
Publicado: (2023)

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors
por: Wang, Xiangxue, et al.
Publicado: (2022)

ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival
por: Harris, Michael A., et al.
Publicado: (2021)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e9c4nn2745gv8bbhkklmfh15dr